An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis (\[AD\]; skin rash, inflammation) that is moderate in severity.

Key facts

Study ID

NCT00455429

Run by

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

People needed

84

Starts

2007-04-01

Expected to finish

2009-03-01

Last updated by the study team

2014-03-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Huntsville, Alabama, United States
• Study site — Los Angeles, California, United States
• Study site — Sacramento, California, United States
• Study site — San Diego, California, United States
• Study site — Stanford, California, United States
• Study site — Vista, California, United States
• Study site — Jacksonville, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Skokie, Illinois, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Rochester, New York, United States
• Study site — Stony Brook, New York, United States
• Study site — Sylvania, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — College Station, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Seattle, Washington, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.